Levetiracetam induces a rapid and sustained reduction of generalized spike-wave and clinical absence

被引:25
作者
Cavitt, J [1 ]
Privitera, M [1 ]
机构
[1] Univ Cincinnati, Inst Neurosci, Dept Neurol, Cincinnati, OH 45267 USA
关键词
D O I
10.1001/archneur.61.10.1604
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Levetiracetam (LEV) is a new antiepileptic drug with efficacy in partial-onset seizures. We report a case in which generalized-onset absence seizures responded clinically and electrographically to LEV. Methods: We evaluated with continuous video/ electroencephalography an adult with generalized-onset seizures given 3 antiepileptic drugs, 1 of which was LEV. Levetiracetam initiation 2 months before admission decreased patient-reported seizures. Interictal electroencephalography revealed generalized 3.5-Hz spike-wave and polyspike-wave discharges. Spike-wave bursts lasting 2 seconds or longer caused a pause in continuous reading aloud, consistent with clinical absence seizures. Levetiracetam was discontinued on admission, lamotrigine was gradually discontinued across 2 days, and topiramate was not changed. One encephalographer counted from video/electroencephalography recordings the number of spike-wave bursts in 1-hour time samples that included wake and sleep time. Results: Spike-wave bursts increased from 4 to 56 per hour at baseline (4000 mg of LEV per day) to 406 to 914 per hour less than 48 hours after LEV discontinuation. Levetiracetam treatment was restarted, and 3 hours after the first dose of 1000 mg, spike-wave bursts dropped to 135 per hour. Response was sustained during the next 2 days. Conclusions: This case showed a dramatic, rapid effect of LEV discontinuation and reinstitution on generalized spike-wave burst frequency and clinical absence. The effects were independent of reduction of lamotrigine and without change in topiramate doses and occurred in a time course consistent with LEV pharmacokinetics. Levetiracetam may be effective in generalized-onset epilepsy, and randomized, controlled trials are indicated.
引用
收藏
页码:1604 / 1607
页数:4
相关论文
共 19 条
[1]   An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day-1 in adult patients with refractory epilepsy [J].
Abou-Khalil, B ;
Hemdal, P ;
Privitera, MD .
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2003, 12 (03) :141-149
[2]   Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: A multicenter, double-blind, responder-selected study evaluating monotherapy [J].
Ben-Menachem, E ;
Falter, T .
EPILEPSIA, 2000, 41 (10) :1276-1283
[3]   Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy [J].
Ben-Menachem, E ;
Gilland, E .
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2003, 12 (03) :131-135
[4]   Clinical experience of marketed Levetiracetam in an epilepsy clinic - a one year follow up study [J].
Betts, T ;
Yarrow, H ;
Greenhill, L ;
Barrett, M .
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2003, 12 (03) :136-140
[5]  
BETTS T, 2002, SEIZURE, V11, P531
[6]   CLINICAL AND EEG ESTIMATES OF ABSENCE SEIZURE FREQUENCY [J].
BROWNE, TR ;
DREIFUSS, FE ;
PENRY, JK ;
WHITE, BG ;
PORTER, RJ .
ARCHIVES OF NEUROLOGY, 1983, 40 (08) :469-472
[7]   Levetiracetam for partial seizures - Results of a double-blind, randomized clinical trial [J].
Cereghino, JJ ;
Biton, V ;
Abou-Khalil, B ;
Dreifuss, F ;
Gauer, LJ ;
Leppik, I .
NEUROLOGY, 2000, 55 (02) :236-242
[8]   Levetiracetam monotherapy for primary generalised epilepsy [J].
Cohen, J .
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2003, 12 (03) :150-153
[9]   Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy [J].
Gower, AJ ;
Hirsch, E ;
Boehrer, A ;
Noyer, M ;
Marescaux, C .
EPILEPSY RESEARCH, 1995, 22 (03) :207-213
[10]   Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy [J].
Grant, R ;
Shorvon, SD .
EPILEPSY RESEARCH, 2000, 42 (2-3) :89-95